This company listing is no longer active
MNKK.Q Stock Overview
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Mallinckrodt plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.02 |
52 Week High | US$0.59 |
52 Week Low | US$0.001 |
Beta | 2.72 |
1 Month Change | -79.38% |
3 Month Change | -83.33% |
1 Year Change | -95.95% |
3 Year Change | -99.78% |
5 Year Change | -99.96% |
Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
MNKK.Q | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -67.2% | -0.2% | 0.6% |
1Y | -96.0% | 23.9% | 29.5% |
Return vs Industry: MNKK.Q underperformed the US Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: MNKK.Q underperformed the US Market which returned -20.6% over the past year.
Price Volatility
MNKK.Q volatility | |
---|---|
MNKK.Q Average Weekly Movement | 27.3% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MNKK.Q's share price has been volatile over the past 3 months.
Volatility Over Time: MNKK.Q's weekly volatility has increased from 21% to 27% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1867 | 2,789 | Mark Trudeau | https://www.mallinckrodt.com |
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products.
Mallinckrodt plc Fundamentals Summary
MNKK.Q fundamental statistics | |
---|---|
Market cap | US$1.70m |
Earnings (TTM) | -US$699.50m |
Revenue (TTM) | US$2.14b |
0.7x
P/S Ratio-2.2x
P/E RatioIs MNKK.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MNKK.Q income statement (TTM) | |
---|---|
Revenue | US$2.14b |
Cost of Revenue | US$1.32b |
Gross Profit | US$817.00m |
Other Expenses | US$1.52b |
Earnings | -US$699.50m |
Last Reported Earnings
Apr 01, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -8.25 |
Gross Margin | 38.15% |
Net Profit Margin | -32.66% |
Debt/Equity Ratio | 712.6% |
How did MNKK.Q perform over the long term?
See historical performance and comparison